Highlights

  • Board approved a workforce reduction of approximately 53% of employees.
  • LUCIA Phase 3 wet AMD study did not meet its primary endpoint.
  • Estimated annualized savings are approximately USD 30 million.
  • Cash and short-term investments were about USD 118 million at September 30, 2026.

EyePoint, Inc. (NASDAQ:EYPT) shares were trading near their all-time low at USD 0.3466 on November 6, 2026, down 2.61% on the day. On October 19, 2026 the company announced a strategic prioritization that includes a workforce reduction of approximately 53% of employees.

EyePoint develops therapeutics for serious retinal diseases. Its lead product candidate is DURAVYU.

LUCIA Readout

The announcement came on the day of the topline readout from the Phase 3 LUCIA study of DURAVYU in wet age related macular degeneration. The study did not meet its primary endpoint of non-inferiority, though the company reported vision improvements. It met key secondary endpoints including reduction in treatment burden, supplement free rates, anatomic control and safety with redosing.

Plan Details

The board approved a plan to reduce the workforce by approximately 53% and to conclude the pivotal Phase 3 wet AMD trials early, without full completion of the second year of each trial. The substantial majority of the reduction is expected in the fourth quarter of 2026, with completion in the first half of 2027.

The company estimates annualized savings of approximately USD 30 million and aggregate one time charges of approximately USD 9 million for employee separation benefits, including severance and related expenses.

DME Program

EyePoint plans to prioritize DURAVYU for diabetic macular edema, with pivotal Phase 3 topline data expected in the fourth quarter of 2027. The program consists of the COMO and CAPRI trials, which enrolled 551 patients in total, about 75% treatment naive and 25% previously treated. Patients were randomized 1:1 to DURAVYU 2.7 mg every six months or on label aflibercept every eight weeks.

The primary endpoint is non-inferiority in average change from baseline in best corrected visual acuity at the blended Weeks 52 and 56. The company cited Phase 2 VERONA data showing sustained visual acuity and over 70% of patients supplement free for six months.

Cash

EyePoint estimated that it had approximately USD 118 million in cash, cash equivalents and short-term investments as of September 30, 2026.